Sep 13, 2021 / 08:15PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Well, great. Good afternoon, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Denali with us for this session.
Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/research disclosures.
And with that, happy to turn it over to Ryan Watts, the CEO of Denali to make some opening comments, and then we can jump right into it.
Ryan J. Watts - Denali Therapeutics Inc. - Co-Founder, President, CEO & Director
Thank you, Matthew. Excellent to be here with you. Again, a little unfortunate that we're here by Zoom, but hey, that's the way that it is. It's been an amazing last year or so at Denali.
I just want to highlight a few points, and then we'll dive into the Q&A.
Denali Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers